Edwards Lifesciences (EW) Tops Q4 EPS by 1c; Guides Above the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Canaccord Genuity Raises Price target on Edwards Lifesciences (EW) as TAVI Continues to Grow
February 3, 2016 10:06 AM ESTCanaccord Genuity reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $92.00 (from $90.00), following the company's 4Q. Checks imply growing acceptance of TAVI as a durable therapy for severe, symptomatic aortic valve disease, with predictable outcomes and consistent results rapidly... More
Edwards Lifesciences (EW) PT, Estimate Raised at Piper Jaffray on Strong 2015 Finish
February 3, 2016 7:42 AM ESTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $97.00 (from $90.00) following a strong finish to 2015 and higher 2016 guidance.
West commented, "Edwards reported Q4 revenues of $671.1M, beating our estimate of $647.7M and consensus $648.8M. Upside... More
